NSE: ACUTAAS · 29 October 2026
- Acutaas Chemicals Ltd. (ACUTAAS) shares advanced 7.19% on Wednesday, closing at ₹3,976.70 after trading within a day's range of ₹3,678.80 and ₹4,030.50.
- Acutaas Chemicals announced its financial results for the quarter ended September 30, 2026, posting revenue from operations of ₹4,369 million, a 42.7% increase year-on-year. EBITDA surged 84.6% to ₹1,760 million with margins expanding to 40.3%, while net profit rose 71.4% to ₹1,231 million. Driven by robust performance in pharmaceutical intermediates and improved gross margins of 62.1%, management upgraded its FY27 revenue growth guidance to around 30% and EBITDA margin guidance to 38-40%.
- Trading volume was 4.04 times the 20-day average daily volume.
Why is Acutaas Chemicals share price rising on 29 October 2026?
Acutaas Chemicals Ltd. (ACUTAAS) shares advanced 7.19% on Wednesday, closing at ₹3,976.70 after trading within a day's range of ₹3,678.80 and ₹4,030.50.
The broader market exhibited positive momentum, with the benchmark Nifty rising 1.05% and the Nifty Metal sector index gaining 0.67%. Acutaas outperformed both headline indices significantly, building on strong prior momentum that includes a 23.68% return over the past 5 trading days and a 20.36% gain over the last 20 trading sessions.
The upward price action follows the company's recent Q2 FY27 earnings release on October 27, 2026, where it reported a 42.7% year-on-year rise in revenue to ₹4,369 million and a 71.4% jump in profit after tax (PAT) to ₹1,231 million. Management also revised its FY27 revenue growth guidance upward from 25% to around 30% and increased its EBITDA margin guidance to 38-40%, supported by strong momentum in its pharmaceutical intermediates business and the early inauguration of its South Korea semiconductor materials facility.
29.20 lakh shares traded by 29 October 2026 · 03:25 PM IST. This compares with a 20-day average daily volume of 7.23 lakh shares (4.04 times). The five-day average daily volume was 17.84 lakh shares. Separately, the NSE report for 28 October 2026 showed 6.98 lakh shares delivered, representing 30.71% of that day’s traded volume. The same report recorded 229,248 trades.
The stock's sharp 7.19% rally accompanied by exceptionally high trading volumes (4.04x the 20-day average) directly aligns with the company's robust Q2 FY27 earnings report and upwardly revised FY27 guidance announced earlier in the week.
Latest Company Developments
Acutaas Chemicals announced its financial results for the quarter ended September 30, 2026, posting revenue from operations of ₹4,369 million, a 42.7% increase year-on-year. EBITDA surged 84.6% to ₹1,760 million with margins expanding to 40.3%, while net profit rose 71.4% to ₹1,231 million. Driven by robust performance in pharmaceutical intermediates and improved gross margins of 62.1%, management upgraded its FY27 revenue growth guidance to around 30% and EBITDA margin guidance to 38-40%.
Demonstrates strong operational execution and provides improved earnings visibility that underpins investor confidence.
The company's step-down subsidiary, Indichem, inaugurated its advanced manufacturing facility in Gongju, Republic of Korea, ahead of schedule. The plant is equipped to produce high-purity chemicals used in photoresists, semiconductor packaging, and etching materials. This expansion positions Acutaas to capture growing demand within the global semiconductor ecosystem.
Expands the company's addressable market into high-value electronic and semiconductor chemical applications.
Acutaas Chemicals completed the acquisition of 100% of the equity share capital of Enchem Ami Organics Private Limited by transferring 10,000 shares from its subsidiary, Acutaas Chemicals Electrolytes Private Limited. With this transaction, the entity has become a direct wholly-owned subsidiary of the company.
Streamlines corporate structure around electrolyte and advanced material operations.
a press release dated October 27, 2026, titled "Q2 & H1 FY27 Results".
Acutaas Chemicals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 14.44% on 30 September 2026. This compares with 14.17% on 30 June 2026, a change of +0.27 percentage points.
The filing reported 32 MF/UTI holders.
What to Watch Next
- Execution and commercial scaling of the newly inaugurated South Korea semiconductor materials facility.
- Sustained delivery percentages against the 30.71% recorded during today's high-volume session.
- Progress on revised FY27 revenue growth guidance of around 30% and 38-40% EBITDA margins.
- Integration milestones following the direct acquisition of Enchem Ami Organics Private Limited.
Other Dated Coverage
- Acutaas Chemicals Share Price Today: Rises 10.79% in 2 Trading Sessions | 28 October 2026 — 28 October 2026
- Acutaas Chemicals Share Price Today: Rises 20.98% in 2 Trading Sessions | 27 October 2026 — 27 October 2026
- Acutaas Chemicals Share Price Today: Why ACUTAAS Is Rising 6.73% | 26 October 2026 — 26 October 2026
More Acutaas Chemicals news and dated analysis →
Frequently Asked Questions
What is the latest Acutaas Chemicals company news?
Acutaas Chemicals announced its financial results for the quarter ended September 30, 2026, posting revenue from operations of ₹4,369 million, a 42.7% increase year-on-year. EBITDA surged 84.6% to ₹1,760 million with margins expanding to 40.3%, while net profit rose 71.4% to ₹1,231 million. Driven by robust performance in pharmaceutical intermediates and improved gross margins of 62.1%, management upgraded its FY27 revenue growth guidance to around 30% and EBITDA margin guidance to 38-40%.
How strong was Acutaas Chemicals’s trading volume?
29.20 lakh shares traded, 4.04 times the 20-day average daily volume. The price and volume data are dated 29 October 2026 · 03:25 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.